Evidence map›Paper›PMID 39979836›Full record

Trial reportBMC cancer2025

The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy.

Nora D Hatletvedt, Christina Engebrethsen, Jürgen Geisler, Stephanie Geisler, Turid Aas, Per E Lønning, Liv B Gansmo, Stian Knappskog

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00496795 (Molecular Markers Predictive Response to Dose Dense Chemotherapy With Epirubicin and Docetaxel in Sequences for Locally Advanced Breast Cancer.), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00496795 phase2unknown statusnot on this map

Molecular Markers Predictive Response to Dose Dense Chemotherapy With Epirubicin and Docetaxel in Sequences for Locally Advanced Breast Cancer.

TypeinterventionalSponsorUniversity of BergenRan2007 to 2026Enrolled100ConditionsStage III Breast Cancer AJCC V7Armsepirubicin/docetaxel sequential
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nora D HatletvedtDepartment of Clinical Science, University of Bergen, 5020, Bergen, Norway.
Christina EngebrethsenDepartment of Clinical Science, University of Bergen, 5020, Bergen, Norway.
Jürgen GeislerDepartment of Oncology, Akershus University Hospital, Lørenskog, Norway.
Stephanie GeislerDepartment of Oncology, Akershus University Hospital, Lørenskog, Norway.
Turid AasDepartment of Surgery, Haukeland University Hospital, Bergen, Norway.
Per E LønningDepartment of Oncology, Haukeland University Hospital, Bergen, Norway.
Liv B GansmoDepartment of Clinical Science, University of Bergen, 5020, Bergen, Norway.
Stian KnappskogDepartment of Clinical Science, University of Bergen, 5020, Bergen, Norway. stian.knappskog@uib.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFunctional polymorphisms in the MDM2 promoters have been linked to cancer risk and several non-malignant conditions. Their potential role in bone marrow function during chemotherapy is largely unknown.

methodsWe investigated the potential associations between genotypes of MDM2 SNP309 (rs2279744), SNP285 (rs117039649) and del1518 (rs3730485) and neutrophil counts in breast cancer patients receiving neoadjuvant sequential epirubicin and docetaxel, with additional G-CSF, in the DDP-trial (NCT00496795). We applied longitudinal ratios, post vs. pre-treatment, of neutrophil counts as our main measure. Differences by genotypes were tested by Jonckheere-Terpstra test for ranked alternatives, while dominant and recessive models were tested by Mann-Whitney U test, and additional sub-analyses were performed for genotype combinations.

resultsThe SNP309 reference T-allele was associated with a better sustained neutrophil count (p = 0.035). A similar association was observed for the alternative del-allele of the del1518 (p = 0.049). Additionally, in combined genotype-analyses, patients with the SNP309 TT genotype and at least one copy of the del1518 del-allele had particularly favorable sustained neutrophil counts during chemotherapy treatment (p = 0.005).

conclusionsOur study provides evidence that MDM2 promoter polymorphisms may be associated with neutrophil counts and bone marrow recovery during chemotherapy treatment in breast cancer patients.

trial registrationThe DDP-trial was registered at ClinicalTrials.gov (NCT00496795; registration date 2007-07-04).

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsNeutrophilsPolymorphism, Single NucleotideProto-Oncogene Proteins c-mdm2AdultAgedDocetaxelEpirubicinFemaleGenotypeHumansLeukocyte CountMiddle AgedNeoadjuvant TherapyTaxoidsDocetaxelEpirubicinMDM2 protein, humanProto-Oncogene Proteins c-mdm2TaxoidsBreast cancerChemotherapyMDM2 polymorphismNeutropenia

Identifiers

PMID39979836
PMCPMC11843751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.